ERK inhibition represses gefitinib resistance in non-small cell lung cancer cells

Gefitinib, an EGFR tyrosine kinase inhibitor, is used to treat non-small cell lung cancer (NSCLC) patients with activating EGFR mutations. However, the resistance to gefitinib eventually emerges in most of the patients. To understand its mechanism, we generated two acquired gefitinib-resistant NSCLC...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncotarget
Main Authors: Qi, Mengfan, Tian, Ye, Li, Wang, Li, Dan, Zhao, Tian, Yang, Yuxin, Li, Qiwen, Chen, Sujun, Yang, Yan, Zhang, Zhixiong, Tang, Liang, Liu, Zhonghua, Su, Bo, Li, Fei, Feng, Yonghong, Fei, Ke, Zhang, Peng, Zhang, Fan, Zhang, Lei
Formato: Artigo
Idioma:Inglês
Publicado em: Impact Journals LLC 2018
Assuntos:
Research Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5844726/
https://ncbi.nlm.nih.gov/pubmed/29552290
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.24147
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados